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Abstract
Analysis of malaria imported into eight European countries from the Indian sub-continent (ISC)
(India, Pakistan, Bangladesh and Sri Lanka) led to a consensus statement on the use of
chemoprophylaxis within TropNetEurop. The proportion of cases from the ISC in 2004 ranged
from 1.4%–4.6% of total imported cases. Plasmodium falciparum cases reported from the eight
countries was only 23 (13% of all cases from the region). Total malaria reports between 1999–2004
fell from 317 to 180. The risk of malaria in UK residents visiting the region was > 1 case per 1,000
years exposed. The group recommended non-selective prescribing of chemoprophylaxis for
visitors to India, Pakistan, Bangladesh and Sri Lanka should be dropped.
Introduction
TropNetEurop is an electronic network which links sur-
veillance data on imported infectious diseases throughout
Europe. The network is designed to identify emerging
trends in regional or global destinations as they affect
European travellers. Sentinel surveillance is carried out by
participating clinical sites using rapid case reporting. This
data can serve as a convenient tool to identify changes rel-
evant to Public Health bodies and focus further investiga-
tions.
A number of countries in the Indian Subcontinent (ISC)
including India, Pakistan, Bangladesh and Sri Lanka con-
tinue to report endemic malaria transmission to the
World Health Organisation [1]. Malaria prevention in
travellers from most European and North American coun-
tries to this region has relied on the use of chemoprophy-
lactic drugs. Although Plasmodium vivax malaria has been
the most frequent species in surveillance reports, ongoing
transmission of Plasmodium falciparum has meant that the
recommended drug regimens have included drugs to pre-
vent both falciparum and vivax malaria. The number of
imported cases of malaria reported from these countries
has been noted to be declining and the continued use of
chemoprophylaxis for travellers to these countries has
been questioned [2]. Switzerland and Germany have dis-
continued recommending chemoprophylaxis and intro-
duced standby therapy for travellers to the ISC [3].
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Discussion
In Sweden, routine chemoprophylaxis for travellers to
India is not recommended [4].
Reports to National malaria surveillance bodies of
malaria cases contracted in the above four countries
between 1999 and 2004 were analysed. The data was pro-
vided through TropNetEurop members who have access
to national data and who could provide details by year
and, where possible, species. The data from the UK was
complemented by data from the International Passenger
Survey (IPS). The IPS is a year round survey of incoming
and outgoing passengers at all major exit ports. Around
0.2% of all travellers are interviewed and this sample pro-
vides estimates of the total annual visits (and their dura-
tion of stay) made by UK residents to individual countries
Table 1: Table shows all cases of all species malaria and cases of Plasmodium falciparum (in brackets) from the ISC, as a proportion of 
total malaria reports in 2004. UK data represents cases occurring in UK residents only and not visitors or immigrants.
1999 2000 2001 2002 2003 2004 ISC % of total malaria 
reports
Switzerland 3.50%
India 16(2) 6 7(2) 6(1) 6 4(1)
Pakistan 0 1 1 0 1 1
Bangladesh 0 0 0 0 0 0
Sri Lanka 5 1 1 1 2(1) 0
United Kingdom 3.50%
India 40(7) 32(5) 25(3) 22(2) 22(1) 29(2)
Pakistan 43(3) 57(1) 50(2) 40(1) 28 38(2)
Bangladesh 0 0 0 1 1 0
Sri Lanka 13(1) 8(2) 12(4) 4(1) 0 1(1)
Germany 1.5%
India 3(1) 6(2) 5(3) 3
Pakistan 0 2(1) 1 0
Bangladesh 1(1) 0 0 0
Sri Lanka 0 0 0 1
France 1.20%
India 19(2) 17(7) 13 (3) 10 (2) 11 (1) 25 (5)
Pakistan 6(2) 6(1) 10 (3) 12 (1) 8 (1) 4 (0)
Bangldesh 1 (0) 1(1) 0 0 1 (0) 1 (1)
Sri Lanka 2 (1) 0 1 (0) 1 (0) 0 3 (0)
Sweden 4.60%
India 7 5(2) 2(1) 4 1 2
Pakistan 1 0 3 1 2 1
Sri Lanka 3 0 0 0 0 0
Bangladesh 0 0 0 0 0 0
Norway 4.17%
India 3 1 3 0 0
Pakistan 4(1) 5 4(2) 1 2 2(1)
Sri Lanka 3 1 1 0 0 0
Bangladesh 1 0 0 0 0 0
Italy 3.00%
India 9(4) 9(1) 5 3 3(1)
Pakistan 1(1) 1 1
Bangladesh 1 0 0 0 0
Sri Lanka 0 1 0 1
Spain 1.53%
India 6(1) 0 2 4(1) 2 6
Pakistan 1 0 0 0 1 1
Bangladesh 0 0 0 0 0 0
Sri Lanka 0 0 0 0 1 0
TropNetEurop* 1.6%
India 14(4) 26(5) 15(6) 14(4) 14(3) 14(2)
Pakistan 5 13(3) 19(4) 11(1) 20(2) 15(2)
Bangladesh 1 1 0 0 0 0
Sri Lanka 1(1) 1
* Cases in TropNetEurop data, may be included in national data sets.
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worldwide. The data from France provided through a
reporting network of 120 selected hospital laboratories
covers approximately half of annual estimates of malaria
cases to the National Reference Centre for Imported and
Autochtonous Malaria Epidemiology (CNREPIA).
The attached table details total cases of malaria acquired
in the ISC by year and species reported to surveillance
bodies of individual European countries (Table 1).
Malaria cases from India make up a very small proportion
of the total reports (range 1.5%–4.6%). The number of
cases of imported P. falciparum from the ISC in 2004 from
reporting countries was 25 of a total of 118 cases. The total
numbers of imported malaria from the 8 countries over
the past three years has been less than 200 per year.
In 2004, UK residents made a total of 1.2 million visits to
the ISC, staying on average 36 (95%CI 27–46) days per
visit. Around 75% of these were made to India and Paki-
stan. These two countries contributed over 95% of the
malaria cases. Analysing all species malaria from these
two countries in 2004, the rate in India (stay 31 days, one
case per 1,923 years exposed) is lower than in Pakistan
(stay 41 days, one case per 1,059 years exposed). The P fal-
ciparum rates are one case per 27,888 in India and 20,112
years exposed in Pakistan. The rates in Sri Lanka and Bang-
ladesh are much lower than these. In France during 2004,
the number of departing travellers to India was 200,000,
to Pakistan 12,000, to Sri Lanka 38,000 and to Bangladesh
2,500 This gives an estimated attack rate for malaria of
respectively, 0.01%, 0.03%, 0.008% and 0.04% per visi-
tor.
One factor which might explain low infection rates is that
most travellers are protected through using chemoproph-
ylaxis. This is not supported in a departure lounge survey
at major European airports, which found only 22% of
travellers to low risk malaria regions carried anti-malaria
drugs[5]. Although the number of visits made from most
other countries is unknown, the numbers of imported
malaria cases reported in countries providing data is often
lower than numbers reported from the UK.
The group consensus was that the likelihood of severe
adverse events (leading to stopping prophylaxis) of a
number of the regularly used prophylactic agents meflo-
quine, chloroquine and proguanil or doxycycline (2–5%)
[6] are significantly higher than the risk of acquiring
malaria in these four countries. Death as a potential severe
outcome needs to be considered. In a series of 618 cases
P. vivax malaria reported to TropNetEurop 1999–2003,
17% were from the ISC and no deaths were reported [7].
Conclusion
In terms of public health policy, the costs and benefits of
prescribing chemoprophylaxis with potential side effects
to large numbers of individuals to prevent small numbers
of non severe malaria cases appears overwhelmingly unfa-
vourable. Although the risk may vary by region and coun-
try within the ISC, this variation is unlikely to be
significantly different given the numbers of cases from the
continent as a whole. The group proposed that the recom-
mendation of non-selective prescribing of chemoprophy-
laxis for visitors to India, Pakistan, Bangladesh and Sri
Lanka should be dropped.
There was complete consensus on continued recommen-
dation of personal protective measures against biting
insects. There was no consensus on provision of standby
treatment to travellers to this region. There were national
differences and limited agreement on appropriate regi-
mens, target groups and duration of journey for which
standby treatment is indicated.
The collaborative analysis of national data enhances epi-
demiological data quality and allows evidence based pol-
icy to be generated and standardised across Europe. This
type of analysis needs to be ongoing to identify trends,
outbreaks or epidemics. Recognising changes in malaria
transmission early is critical to re-adjusting policy and
assuring optimal protection of travellers. Careful monitor-
ing of cases acquired from this region after a change in
policy will be necessary to detect changing malaria epide-
miology amongst travellers.
Authors' contributions
RB conceived, designed and co-ordinated the study. TJ
organised and chaired the policy group meeting. RB, AB,
JG, CH, FL, NM and PV obtained and prepared data and
contributed to policy and manuscript preparation. All
authors read and approved the final manuscript.
Acknowledgements
Malaria Reference Laboratory, Health Protection Agency UK (Peter Chi-
odini)
SIMPID – Surveillance importierter Infektionen in Deutschland (Nikolai 
Mühlberger)
Section of Infectious Disease Prevention and Control, the Norwegian Insti-
tute of Public Health (Hans Blystad)
Swedish Institute for Infectious Disease Control (Andreas Martensson and 
Lars Rombo)
Centro Nacional de Epidemiologia ISCIII, Madrid (Luisa P. Sanchez)
Dipartimento di Malattie Infettive, Parassitarie e Immunomediate Istituto 
Superiore di Sanità and Ministero della Salute, Direzione Generale della 
Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Malaria Journal 2006, 5:7 http://www.malariajournal.com/content/5/1/7
Page 4 of 4
(page number not for citation purposes)
Prevenzione, Ufficio V, Malattie Infettive e Profilassi Internazionale, Rome 
(Roberto Romi)
Consultation de médecine tropicale, Hôpital Avicenne, Bobigny, France 
(Olivier Bouchaud)
Communicable diseases unit, Swiss Federal Office of Public Health (Simone 
Graf)
References
1. Organization WH: Malaria. Disease Burden in SEA Region.
2005 [http://w3.whosea.org/EN/Section10/Section21/
Section340_4018.htm]. The World Health Organization. Regional
Office for South-East Asia
2. Rombo L: Who needs drug prophylaxis against malaria? My
personal view.  J Travel Med 2005, 12:217-221.
3. Hatz C, Beck B, Blum J, Funk M, Furrer HJ, Genton B, Holzer B, Lou-
tan L, Markwalder K, Raeber PA, Schlagenhauf P, Siegl G, Steffen R,
Wyss R: Änderung der Empfehlungen zum Malariaschutz für
Reisende nach Südasian (Indien, Bangladesh, Nepal) .  Bulletin
des Bundesamtes fur Gesundheit 2005, 9:138-139.
4. The Swedish reference group for malaria prophylaxis: Swedish
Malaria Guidelines.  Smittskydd 2004, 3:1-16.
5. Van Herck K, Van Damme P, Castelli F, Zuckerman J, Nothdurft H,
Dahlgren AL, Gisler S, Steffen R, Gargalianos P, Lopez-Velez R, Over-
bosch D, Caumes E, Walker E: Knowledge, attitudes and prac-
tices in travel-related infectious diseases: the European
airport survey.  J Travel Med 2004, 11:3-8.
6. Schlagenhauf P, Tschopp A, Johnson R, Nothdurft HD, Beck B,
Schwartz E, Herold M, Krebs B, Veit O, Allwinn R, Steffen R: Toler-
ability of malaria chemoprophylaxis in non-immune travel-
lers to sub-Saharan Africa: multicentre, randomised, double
blind, four arm study.  BMJ 2003, 327:1078.
7. Muhlberger N, Jelinek T, Gascón J, Probst M, Zoller T, Schunk M,
Beran J, Gjorup I, Behrens RH, Clerinx J, Bjorkman A, McWhinney P,
Matteelli A, Lopez-Velez R, Bisoffi Z, Hellgren U, Puente S, Schmid M,
Myrvang B, Holthoff-Stich M, Laferl H, Hatz C, Kollaritsch H, Kapaun
A, Knobloch J, Iversen J, Kotlowski A, Malvy D, Kern P, Fry G, Siika-
maki H, Schulze M, Soula G, Paul M, Prat JG, Lehmann V, Bouchaud
O, da Cunha S, Atouguia J, Boecken G: Epidemiology and clinical
features of vivax malaria imported to Europe: Sentinel sur-
veillance data from TropNetEurop.  Malar J 2004, 3:5.
